Cogent Biosciences (COGT) Net Cash Flow (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Net Cash Flow data on file, last reported at -$70.8 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 354.34% year-over-year to -$70.8 million in Q1 2026; TTM through Mar 2026 was $115.6 million, a 228.76% increase from a year earlier, with the FY2025 full-year figure at $214.3 million, up 376.82% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$70.8 million, down from $186.8 million in the prior quarter.
• Over the last five years, Net Cash Flow for COGT reached as high as $186.8 million in Q4 2025 and fell as low as -$185.0 million in Q3 2022.
• Historically, Net Cash Flow has averaged $1.2 million across 5 years, with a median of $1.1 million in 2024.
• Across the five-year window, Net Cash Flow plunged 4823.9% in 2023 and surged 16578.12% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$682000.0 in 2022, then plunged by 4823.9% to -$33.6 million in 2023, then surged by 103.34% to $1.1 million in 2024, then jumped by 16578.12% to $186.8 million in 2025, then plunged by 137.9% to -$70.8 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$70.8 million in Q1 2026, $186.8 million in Q4 2025, and -$2.0 million in Q3 2025.